Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease

References

• Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–1605. doi:10.1016/S0140-6736(12)60026-9.
   PubMed Web of Science ®Google Scholar
• Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380:1606–1619. doi:10.1016/S0140-6736(12)60150-0.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, et al. Crohn’s disease: beyond antagonists of tumour necrosis factor. Lancet. 2008;372:67–81. doi:10.1016/S0140-6736(08)60995-2.
   PubMed Web of Science ®Google Scholar
• Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn’s disease. Lancet. 1993;342:173–174. doi:10.1016/0140-6736(93)91375-V.
   PubMed Web of Science ®Google Scholar
• van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129–135. doi:10.1016/0016-5085(95)90277-5.
   PubMed Web of Science ®Google Scholar
• Singh S, Garg SK, Pardi DS, et al. Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis. Mayo Clin Proc. 2014;89:1621–1635. doi:10.1016/j.mayocp.2014.08.019.
   PubMed Web of Science ®Google Scholar
• Stidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39:1349–1362. doi:10.1111/apt.12749.
   PubMed Web of Science ®Google Scholar
• Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. Gastroenterology. 2015;148:344–54.e5;quiz e14–5. doi:10.1053/j.gastro.2014.10.011.
   Web of Science ®Google Scholar
• Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160:704–711. doi:10.7326/M13-2403.
   PubMed Web of Science ®Google Scholar
• Stidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39:660–671. doi:10.1111/apt.12644.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol. 2014;12:929–34.e2. doi:10.1016/j.cgh.2013.07.022.
   PubMed Web of Science ®Google Scholar
• Pineton de Chambrun G, Blanc P, Peyrin-Biroulet L. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2016;1–13. doi:10.1586/17474124.2016.1174064. Epub 2016 Apr 18.
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Fiorino G, Buisson A, et al. First-line therapy in adult Crohn’s disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol. 2013;10:345–351. doi:10.1038/nrgastro.2013.31.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn’s disease. Expert Opin Drug Saf. 2016;15:493–501.
   PubMed Web of Science ®Google Scholar
• Rinaudo-Gaujous M, Paul S, Tedesco ED, et al. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther. 2013;38:914–924. doi:10.1111/apt.12477.
   PubMed Web of Science ®Google Scholar
• Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537–545. doi:10.1038/nrgastro.2015.135.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Billioud V, D’Haens G, et al. Development of the Paris definition of early Crohn’s disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012;107:1770–1776. doi:10.1038/ajg.2012.117.
   PubMed Web of Science ®Google Scholar
• Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2003;18:425–431. doi:10.1046/j.1365-2036.2003.01672.x.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Colombel J-F, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn’s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105:1574–1582. doi:10.1038/ajg.2010.78.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J Crohns Colitis. 2013;7:213–221. doi:10.1016/j.crohns.2012.10.011.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371:660–667. doi:10.1016/S0140-6736(08)60304-9.
   PubMed Web of Science ®Google Scholar
• Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet. 2015;386:1825–1834. doi:10.1016/S0140-6736(15)00068-9.
   PubMed Web of Science ®Google Scholar
• Nuij V, Fuhler GM, Edel AJ, et al. Benefit of earlier anti-TNF treatment on IBD disease complications? J Crohns Colitis. 2015;9:997–1003. doi:10.1093/ecco-jcc/jjv130.
   PubMed Web of Science ®Google Scholar
• Safroneeva E, Vavricka SR, Fournier N, et al. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn’s disease. Aliment Pharmacol Ther. 2015;42:977–989. doi:10.1111/apt.13365.
   PubMed Web of Science ®Google Scholar
• Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991–1030. doi:10.1016/j.crohns.2012.09.002.
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Panaccione R, Higgins PDR, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199–212;quiz 213. doi:10.1038/ajg.2010.392.
   PubMed Web of Science ®Google Scholar
• Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4:28–62. doi:10.1016/j.crohns.2009.12.002.
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405. doi:10.1056/NEJM199905133401909.
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–885. doi:10.1056/NEJMoa030815.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009;58:940–948. doi:10.1136/gut.2008.159251.
   PubMed Web of Science ®Google Scholar
• Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63:292–299. doi:10.1136/gutjnl-2013-304488.
   PubMed Web of Science ®Google Scholar
• van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107–124. doi:10.1093/ecco-jcc/jju006.
   PubMed Web of Science ®Google Scholar
• Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33:1053–1058. doi:10.1111/j.1365-2036.2011.04617.x.
   PubMed Web of Science ®Google Scholar
• Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016. doi:10.1053/j.gastro.2016.04.002.
   PubMed Web of Science ®Google Scholar
• Damas OM, Deshpande AR, Avalos DJ, et al. Treating inflammatory bowel disease in pregnancy: the issues we face today. J Crohns Colitis. 2015;9:928–936. doi:10.1093/ecco-jcc/jjv118.
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Bentele N, Scharl M, et al. Systematic assessment of factors influencing preferences of Crohn’s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis. 2012;18:1523–1530. doi:10.1002/ibd.21888.
   PubMed Web of Science ®Google Scholar
• Kim ES, Kim KO, Jang BI, et al. Factors contributing to the preference of Korean patients with Crohn’s disease when selecting an anti-tumor necrosis factor agent (CHOICE study). Gut Liver. 2016;10:391–398.
   Web of Science ®Google Scholar
• Lopez A, Billioud V, Peyrin-Biroulet C, et al. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis. 2013;19:1528–1533. doi:10.1097/MIB.0b013e31828c8512.
   PubMed Web of Science ®Google Scholar
• Fidder HH, Singendonk MMJ, van der Have M, et al. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol. 2013;19:4344–4350. doi:10.3748/wjg.v19.i27.4344.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Vermeire S, Ballet V, et al. Switch to adalimumab in patients with Crohn’s disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut. 2012;61:229–234. doi:10.1136/gutjnl-2011-300755.
   PubMed Web of Science ®Google Scholar
• Hoentjen F, Haarhuis BJT, Drenth JPH, et al. Elective switching from infliximab to adalimumab in stable Crohn’s disease. Inflamm Bowel Dis. 2013;19:761–766. doi:10.1097/MIB.0b013e3182802ae1.
   PubMed Web of Science ®Google Scholar
• Bhalme M, Sharma A, Keld R, et al. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn’s disease? Eur J Gastroenterol Hepatol. 2013;25:543–549. doi:10.1097/MEG.0b013e32835d1f15.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–767. doi:10.1038/ajg.2008.88.
   PubMed Web of Science ®Google Scholar
• Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol. 2011;106:674–684. doi:10.1038/ajg.2011.60.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395. doi:10.1056/NEJMoa0904492.
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392–400.e3. doi:10.1053/j.gastro.2013.10.052.
   PubMed Web of Science ®Google Scholar
• Feagan BG, McDonald JWD, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146:681–8.e1. doi:10.1053/j.gastro.2013.11.024.
   PubMed Web of Science ®Google Scholar
• Narula N, Peyrin-Biroulet L, Colombel J-F. Combination therapy with methotrexate in inflammatory bowel disease: time to COMMIT? Gastroenterology. 2014;146:608–611. doi:10.1053/j.gastro.2014.01.040.
   PubMed Web of Science ®Google Scholar
• Jones JL, Kaplan GG, Peyrin-Biroulet L, et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn’s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2015;13:2233–40.e2. doi:10.1016/j.cgh.2015.06.034.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Motoya S, Watanabe K, et al. Comparison of adalimumab monotherapy and a combination with azathioprine for patients with Crohn’s disease: a prospective, multicentre, open-labelled clinical trial (DIAMOND study). J Crohns Colitis. 2016;10:S8.
   Google Scholar
• Osterman MT, Haynes K, Delzell E, et al. Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:1293–301.e5;quiz e70, e72. doi:10.1016/j.cgh.2015.02.017.
   Web of Science ®Google Scholar
• Peyrin-Biroulet L, Salleron J, Filippi J, et al. Anti-TNF monotherapy for Crohn’s disease: a 13-year multicentre experience. J Crohns Colitis. 2016. Epub 2016 Jan 22. doi:10.1093/ecco-jcc/jjw008.
   Web of Science ®Google Scholar
• Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease - algorithm for practical management. Aliment Pharmacol Ther. 2016;43:30–51. doi:10.1111/apt.2016.43.issue-1.
   PubMed Web of Science ®Google Scholar
• Billiet T, Rutgeerts P, Ferrante M, et al. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opin Biol Ther. 2014;14:75–101. doi:10.1517/14712598.2014.858695.
   PubMed Web of Science ®Google Scholar
• Gibson DJ, Heetun ZS, Redmond CE, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:330–5.e1. doi:10.1016/j.cgh.2014.07.041.
   PubMed Web of Science ®Google Scholar
• Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2015;41:1094–1103. doi:10.1111/apt.13175.
   PubMed Web of Science ®Google Scholar
• Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149:350–5.e2. doi:10.1053/j.gastro.2015.04.016.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24–30. doi:10.1016/j.autrev.2013.06.002.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21:182–197. doi:10.1097/MIB.0000000000000202.
   PubMed Web of Science ®Google Scholar
• Eshuis EJ, Bemelman WA, van Bodegraven AA, et al. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn’s disease: a randomized multicenter trial (LIR!C-trial). BMC Surg BioMed Central. 2008;8:15. doi:10.1186/1471-2482-8-15.
   PubMedGoogle Scholar
• Ho G-T, Smith L, Aitken S, et al. The use of adalimumab in the management of refractory Crohn’s disease. Aliment Pharmacol Ther. 2008;27:308–315. doi:10.1111/j.1365-2036.2007.03583.x.
   PubMed Web of Science ®Google Scholar
• Swaminath A, Ullman T, Rosen M, et al. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. Aliment Pharmacol Ther. 2009;29:273–278. doi:10.1111/j.1365-2036.2008.03878.x.
   PubMed Web of Science ®Google Scholar
• Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31:92–101. doi:10.1111/j.1365-2036.2009.04130.x.
   PubMed Web of Science ®Google Scholar
• Löfberg R, Louis EV, Reinisch W, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn’s disease: results from CARE. Inflamm Bowel Dis. 2012;18:1–9. doi:10.1002/ibd.21663.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Rivals O, Billiet T, et al. Long-term outcome of IBD patients with primary non-response to anti-TNF therapy. J Crohns Colitis. 2015;9:S– 58.
   Google Scholar
• Siegel CA, Melmed GY. Predicting response to anti-TNF agents for the treatment of crohn’s disease. Therap Adv Gastroenterol. 2009;2:245–251.
   PubMedGoogle Scholar
• Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33:987–995. doi:10.1111/j.1365-2036.2011.04612.x.
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–608. doi:10.1056/NEJMicm020037.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108:962–971. doi:10.1038/ajg.2013.12.
   PubMed Web of Science ®Google Scholar
• Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63:1258–1264. doi:10.1136/gutjnl-2013-305259.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126:402–413. doi:10.1053/j.gastro.2003.11.014.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56:1226–1231. doi:10.1136/gut.2006.099978.
   PubMed Web of Science ®Google Scholar
• Torres J, Boyapati RK, Kennedy NA, et al. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology. 2015;149:1716–1730. doi:10.1053/j.gastro.2015.08.055.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Marín AC, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther. 2015;42:391–405. doi:10.1111/apt.13365.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861–1868. doi:10.1053/j.gastro.2008.01.074.
   PubMed Web of Science ®Google Scholar
• Oussalah A, Chevaux J-B, Fay R, et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn’s disease treated with combination therapy. Am J Gastroenterol. 2010;105:1142–1149. doi:10.1038/ajg.2010.158.
   PubMed Web of Science ®Google Scholar
• Drobne D, Bossuyt P, Breynaert C, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:514–21.e4. doi:10.1016/j.cgh.2014.07.027.
   PubMed Web of Science ®Google Scholar
• Louis E, Mary J-Y, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63–70.e5;quiz e31. doi:10.1053/j.gastro.2011.09.034.
   Web of Science ®Google Scholar
• Molnár T, Lakatos PL, Farkas K, et al. Predictors of relapse in patients with Crohn’s disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther. 2013;37:225–233. doi:10.1111/apt.12160.
   PubMed Web of Science ®Google Scholar
• Waugh AWG, Garg S, Matic K, et al. Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther. 2010;32:1129–1134. doi:10.1111/j.1365-2036.2010.04446.x.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Molazahi A, Ainsworth MA, et al. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol. 2012;47:518–527. doi:10.3109/00365521.2012.660541.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y, Ungar B, et al. Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. Aliment Pharmacol Ther. 2015;42:356–364. doi:10.1111/apt.13365.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Marín AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2016;111:632–647. doi:10.1038/ajg.2016.54.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320–9.e3. doi:10.1053/j.gastro.2015.02.031.
   PubMed Web of Science ®Google Scholar
• Williet N, Paul S, Peyrin-Biroulet L, et al. Pharmacokinetics of infliximab and reduction of treatment for inflammatory bowel diseases. Dig Dis Sci. 2016;61:990–995. doi:10.1007/s10620-015-3984-2.
   PubMed Web of Science ®Google Scholar
• Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24:1–10. doi:10.3904/kjim.2009.24.3.279.
   PubMedGoogle Scholar
• Felice C, Marzo M, Pugliese D, et al. Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases. Expert Opin Biol Ther. 2015;15:1107–1117. doi:10.1517/14712598.2015.1044434.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Brynskov J, Thomsen OØ, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63:919–927. doi:10.1136/gutjnl-2013-305279.
   PubMed Web of Science ®Google Scholar
• D’haens G, Vermeire S, Lambrecht G, et al. Drug-concentration versus symptom-driven dose adaptations of Infliximab in patients with active Crohn’s disease: a prospective, randomised, multicentre trial (Tailorix). J Crohns Colitis. 2016;10:S24.
   Web of Science ®Google Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612. doi:10.1136/annrheumdis-2012-203091.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620. doi:10.1136/annrheumdis-2012-203090.
   PubMed Web of Science ®Google Scholar
• Brodszky V, Baji P, Balogh O, et al. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ. 2014;15(Suppl 1):S65–71. doi:10.1007/s10198-014-0595-3.
   PubMed Web of Science ®Google Scholar
• Schreiber S. An update on biosimilar drugs for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):1–3. doi:10.1586/17474124.2014.940897.
   PubMed Web of Science ®Google Scholar
• Kang Y-S, Moon HH, Lee SE, et al. Clinical experience of the use of CT-P13, a Biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60:951–956. doi:10.1007/s10620-014-3392-z.
   PubMed Web of Science ®Google Scholar
• Jung YS, Park D Il, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30:1705–1712. doi:10.1111/jgh.12997.
   PubMed Web of Science ®Google Scholar
• Gecse KB, Lovász BD, Farkas K, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis. 2016;10:133–140. doi:10.1093/ecco-jcc/jjv220.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Yavzori M, Benhar I, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2016;65:1132–1138.
   PubMed Web of Science ®Google Scholar
• Bettey M, Downey L, Underhill C, et al. Outcomes of a managed switching programme changing IBD patients established or originator infliximab to biosimilar infliximab. J Crohns Colitis. 2016;10:S43–4.
   PubMedGoogle Scholar
• Smits L, Derikx L, Drenth J, et al. Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016;10:S44–5. doi:10.1093/ecco-jcc/jjw019.059.
   Web of Science ®Google Scholar
• Kolar M, Duricova D, Brotlik M, et al. Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (RemsimaTM) is effective and safe. J Crohns Colitis. 2016;10:S45–6.
   Google Scholar
• Lovasz B, Kurti Z, Rutka M, et al. Immunogenicity profile and predictors of TLs and ADA development of biosimilar infliximab during the first 6 months of the therapy: results from a prospective nationwide cohort. J Crohns Colitis. 2016;10:S46.
   Google Scholar
• Salaffi F, Carotti M, Di Carlo M, et al. Adherence to anti-tumor necrosis factor therapy administered subcutaneously and associated factors in patients with rheumatoid arthritis. J Clin Rheumatol. 2015;21:419–425. doi:10.1097/RHU.0000000000000320.
   PubMed Web of Science ®Google Scholar
• Bhol KC, Tracey DE, Lemos BR, et al. AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2273–2281. doi:10.1097/MIB.0b013e31828c8512.
   PubMed Web of Science ®Google Scholar
• Harris MS, Hartman D, Lemos BR, et al. AVX-470, an orally delivered anti-TNF antibody for treatment of active ulcerative colitis: results of a first-in-human trial. J Crohns Colitis. 2016. Epub 2016 Jan 28. doi:10.1093/ecco-jcc/jjw036.
   Web of Science ®Google Scholar
• Hartman DS, Tracey DE, Lemos BR, et al. Effects of AVX-470, an oral, locally acting anti-tumour necrosis factor antibody, on tissue biomarkers in patients with active ulcerative colitis. J Crohns Colitis. 2016. Epub 2016 Jan 22. doi:10.1093/ecco-jcc/jjw026.
   Web of Science ®Google Scholar
• Semerano L, Assier E, Delavallée L, et al. Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis. Expert Opin Biol Ther. 2011;11:545–550. doi:10.1517/14712598.2011.566856.
   PubMed Web of Science ®Google Scholar
• Durez P, Vandepapeliere P, Miranda P, et al. Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial. PLoS One. 2014;9:e113465. doi:10.1371/journal.pone.0113465.
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–2078. doi:10.1056/NEJMra0804647.
   PubMed Web of Science ®Google Scholar
• Gu J, Ghayur T. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting. Methods Enzymol. 2012;502:25–41.
   PubMed Web of Science ®Google Scholar
• Lacy SE, Wu C, Ambrosi DJ, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. MAbs. 2015;7:605–619. doi:10.1080/19420862.2015.1026501.
   PubMed Web of Science ®Google Scholar
• Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with −308 TNF gene polymorphism. Scand J Gastroenterol. 2002;37:818–824.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Wang Y, Oddens BJ, et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn’s disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012;35:568–576. doi:10.1111/j.1365-2036.2011.04987.x.
   PubMed Web of Science ®Google Scholar
• Jürgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2011;9:421–7.e1. doi:10.1016/j.cgh.2011.02.008.
   PubMed Web of Science ®Google Scholar
• Magro F, Rodrigues-Pinto E, Santos-Antunes J, et al. High C-reactive protein in Crohn’s disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis. 2014;8:129–136. doi:10.1016/j.crohns.2013.07.005.
   PubMed Web of Science ®Google Scholar
• Florin THJ, Paterson EWJ, Fowler EV, et al. Clinically active Crohn’s disease in the presence of a low C-reactive protein. Scand J Gastroenterol. 2006;41:306–311. doi:10.1080/00365520500217118.
   PubMed Web of Science ®Google Scholar
• Hibi T, Sakuraba A, Watanabe M, et al. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease. J Gastroenterol. 2014;49:254–262. doi:10.1007/s00535-013-0895-x.
   PubMed Web of Science ®Google Scholar
• Pierik M, Vermeire S, Steen KV, et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther. 2004;20:303–310. doi:10.1111/j.1365-2036.2004.01946.x.
   PubMed Web of Science ®Google Scholar
• Oliver J, Plant D, Webster AP, et al. Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis. Biomark Med. 2015;9:499–512. doi:10.2217/bmm.15.18.
   PubMed Web of Science ®Google Scholar
• Tong Q, Zhao L, Qian X-D, et al. Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis. Pharmacogenomics. 2013;14:1691–1700. doi:10.2217/pgs.13.146.
   PubMed Web of Science ®Google Scholar
• Matsukura H, Ikeda S, Yoshimura N, et al. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn’s disease. Aliment Pharmacol Ther. 2008;27:765–770. doi:10.1111/j.1365-2036.2008.03630.x.
   PubMed Web of Science ®Google Scholar
• Medrano LM, Taxonera C, Márquez A, et al. Role of TNFRSF1B polymorphisms in the response of Crohn’s disease patients to infliximab. Hum Immunol. 2014;75:71–75. doi:10.1016/j.humimm.2014.05.004.
   PubMed Web of Science ®Google Scholar
• Billiet T, Cleynen I, Ferrante M, et al. A variable number of tandem repeat polymorphism in the promotor region of the neonatal Fc receptor affects anti-tumour necrosis factor serum levels in inflammatory bowel disease. J Crohns Colitis. 2016;10:S3.
   PubMedGoogle Scholar
• Toedter G, Li K, Marano C, et al. Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis. Am J Gastroenterol. 2011;106:1272–1280. doi:10.1038/ajg.2011.83.
   PubMed Web of Science ®Google Scholar
• Arijs I, Quintens R, Van Lommel L, et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn’s disease. Inflamm Bowel Dis. 2010;16:2090–2098. doi:10.1002/ibd.21253.
   PubMed Web of Science ®Google Scholar
• Atreya R, Neumann H, Neufert C, et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med. 2014;20:313–318. doi:10.1038/nm.3462.
   PubMed Web of Science ®Google Scholar
• Kapoor SR, Filer A, Fitzpatrick MA, et al. Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65:1448–1456. doi:10.1002/art.37921.
   PubMed Web of Science ®Google Scholar
• Billiet T, Papamichael K, De Bruyn M, et al. A matrix-based model predicts primary response to infliximab in Crohn’s disease. J Crohns Colitis. 2015;9:1120–1126. doi:10.1093/ecco-jcc/jjv156.
   PubMed Web of Science ®Google Scholar
• Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14:550–7.e2. doi:10.1016/j.cgh.2015.10.025.
   PubMed Web of Science ®Google Scholar
• Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013;19:2568–2576. doi:10.1097/MIB.0b013e31828c8512.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice. J Clin Pharmacol. 2015;55(Suppl 3):S39–50. doi:10.1016/j.cgh.2015.11.014.
   PubMed Web of Science ®Google Scholar
• Sharma S, Eckert D, Hyams JS, et al. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn’s disease: results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis. 2015;21:783–792. doi:10.1097/MIB.0000000000000327.
   PubMed Web of Science ®Google Scholar
• Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63:1721–1727. doi:10.1136/gutjnl-2012-304094.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Van Stappen T, Vande Casteele N, et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;14:543–549. doi:10.1016/j.cgh.2015.11.014.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Suzuki Y, Motoya S, et al. Factors associated with the first trough level of infliximab at week 2 that predicts short- and long-term outcomes in ulcerative colitis. J Crohns Colitis. 2016;10:S24–5.
   Google Scholar
• Mould DR, Dubinsky MC. Dashboard systems: pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. J Clin Pharmacol. 2015;55(Suppl 3):S51–9. doi:10.1002/jcph.370.
   PubMed Web of Science ®Google Scholar
• Lu J, Van Stappen T, Spasic D, et al. Fiber optic-SPR platform for fast and sensitive infliximab detection in serum of inflammatory bowel disease patients. Biosens Bioelectron. 2016;79:173–179. doi:10.1016/j.bios.2015.11.087.
   PubMed Web of Science ®Google Scholar
• The NOR-SWITCH study. (cited 2016 Mar 14]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02148640
   Google Scholar
• Andersen NN, Jess T. Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol. 2014;20:16014–16019. doi:10.3748/wjg.v20.i43.16014.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72:517–524. doi:10.1136/annrheumdis-2011-201244.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Vutcovici M, Kezouh A, et al. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database Study. Inflamm Bowel Dis. 2015;21:1847–1853. doi:10.1097/MIB.0000000000000457.
   PubMed Web of Science ®Google Scholar
• Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20:119–130. doi:10.1002/pds.2046.
   PubMed Web of Science ®Google Scholar
• Nardone B, Hammel JA, Raisch DW, et al. Melanoma associated with tumour necrosis factor-α inhibitors: a research on adverse drug events and reports (RADAR) project. Br J Dermatol. 2014;170:1170–1172. doi:10.1111/bjd.12779.
   PubMed Web of Science ®Google Scholar
• IBD Cancer and Serious infection in Europe (I-CARE). [cited 2016 Mar 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02377258
   Google Scholar
• Del Tedesco E, Paul S, Marotte H, et al. Azathioprine dose reduction in patients with inflammatory bowel disease on combination therapy: a prospective study. J Crohns Colitis. 2016;10:S7.
   Google Scholar
• Enhanced Algorithm for Crohn’s Treatment Incorporating Early Combination Therapy (REACT2). [cited 2016 Mar 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT01698307
   Google Scholar
• Efficacy and safety of two treatment models in subjects with moderate-to-severe Crohn’s disease (CALM). [cited 2016 Mar 12]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01235689
   Google Scholar